Pregnancy, Contraception, and Menopause in Advanced Chronic Kidney Disease and Kidney Transplant

Virginia A. Dines,1 Vesna D. Garovic,1,2 Santosh Parashuram,1 Fernando G. Cosio,1 and Andrea G. Kattah1,i,*

Abstract

Background: Reproductive health is an essential part of the care of women with kidney disease. However, the self-reported patient experience of reproductive issues has been underexplored.

Materials and Methods: We identified a cohort of women ages 18 to 44 at the time of kidney transplant from 1996 to 2014 at our 3-site program (n = 816). We sent each woman a survey on her reproductive lifespan, characterizing features from menarche to menopause.

Results: We received survey responses from 190 patients (27%). One third of respondents reported amenorrhea before transplant, and 61.5% of these women reported resumption of menses post-transplant. The average age of menopause was 45.5 years, earlier than the general population (51.3 years). There were 204 pregnancies pre-transplant and 52 pregnancies post-transplant. Pregnancies post-transplant were more likely to be complicated by preeclampsia, preterm delivery, and small for gestational age babies than pregnancies that occurred >5 years before transplant. Pregnancies <5 years before transplant were similar to post-transplant pregnancies with respect to complications. Forty-two percent of women were advised to avoid pregnancy after transplant, most often by a nephrology provider.

Conclusions: In our cohort of kidney transplant recipients, women report increased pregnancy-related complications post-transplant and in the 5 years before transplant, compared with pregnancies that occurred greater than 5 years before transplant. They were often counseled to avoid pregnancy altogether. Women reported a younger age of menopause relative to the general population. This should be considered when counseling patients with chronic kidney disease regarding optimal pregnancy timing.

Keywords: chronic kidney disease; kidney transplant; contraception; menopause; pregnancy

Introduction

Reproductive health is an important aspect of medical care for women with chronic kidney disease (CKD) and kidney transplants. Women with CKD are considered a high-risk population in pregnancy, as there is a significantly increased risk of pregnancy-related complications and adverse maternal and fetal outcomes.1–4 Additionally, CKD affects fertility and patients may struggle to conceive.5 Post-transplant, women often have improved fertility; however, pregnancy post-transplant has additional risks, including potential exposure to teratogenic medications and increased risk of pregnancy complications and adverse outcomes compared with the general population.6 Women are often advised to wait until after a successful kidney transplant to pursue pregnancy, and major society

1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
2Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.
3ORCID ID (https://orcid.org/0000-0001-7228-9876).
4Address correspondence to: Andrea G. Kattah, MD, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA, E-mail: kattah.andrea@mayo.edu

© Virginia A. Dines et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
guidelines recommend waiting to conceive 1–2 years post-transplant, depending on individual risk factors.\textsuperscript{7}

For women in the advancing stages of CKD, planning a pregnancy can be further complicated by factors such as deterioration of kidney function, which could lead to the need for dialysis, and declining age-related fertility while awaiting a donor.\textsuperscript{8} As neonatal care has improved, as well as maternal and fetal outcomes of women on dialysis, whether to pursue pregnancy before or after transplant is less clear.\textsuperscript{9,10} Furthermore, data on the effects of pregnancy on kidney transplant outcomes have been limited and have shown mixed results, which complicates decision making regarding the optimal timing of pregnancy.\textsuperscript{6,11–13} Ideally, a multidisciplinary team, including obstetricians/gynecologists and nephrologists, can offer an individualized approach to each patient. Given the medical complexity and the multitude of personal factors involved in pursuing pregnancy, it is essential to better understand patients’ experiences with reproductive issues.

The objective of this study was to better understand the reproductive health experiences of women who have had kidney transplants. Previous studies largely have focused on pregnancy-related clinical outcomes in CKD or post-transplant, or on individual components of reproductive health. However, several factors have been underexplored, including how many women have attempted pregnancy, how many have been advised against pursuing pregnancy, whether pregnancies post-transplant have more or fewer complications than pregnancies pretransplant, and whether a transplant could impact the timing of menopause, and therefore the “fertile window” after transplant. By answering the above questions, we hoped to identify gaps in knowledge for future study, as well as provide information to better guide counseling and care.

**Materials and Methods**

We identified women ages 18 to 44 at the time of kidney transplant, from the years 1996 to 2014 at all three Mayo Clinic sites: Rochester, MN; Scottsdale, AZ; and Jacksonville, FL. We sent all women a survey at their most recent address. If women did not respond to the first survey, a second survey was sent. We followed up with a phone call after the second survey and resent a survey to women who wanted to participate. All survey responses were entered into a database. All subjects who declined to participate, either by phone or mail, were counted as refusals. This study was approved by the Institutional Review Board at Mayo Clinic.

**Transplant recipient characteristics**

A manual chart review was performed using the 3-site transplant database. We recorded demographics at the time of transplant, including age and race, as well type of transplant (deceased vs. living donors), parity at time of transplant (any prior pregnancy vs. none), number of pregnancies before and after transplant, and body mass index (BMI).

**Survey**

The survey was adapted from several existing surveys in collaboration with the Survey Research Center at Mayo Clinic, including the National Transplantation Pregnancy Registry,\textsuperscript{14} a previously validated survey on hypertension in pregnancy,\textsuperscript{15} and internal surveys used for clinical care in the Women’s Health Clinic. The focus of the survey was general reproductive health, including pregnancy history before and after transplant, change in menstrual periods before and after transplant, use of contraception, and menopausal characteristics.

**Pregnancy history**

We asked about the total number of pregnancies before and after kidney transplant and the outcomes of pregnancy, including the number of live births, stillbirths, neonatal deaths (death within the first 7 days of life), miscarriages, and elective abortions. We asked about whether each pregnancy lasting longer than 20 weeks had been planned, the gestational age at delivery, the number, sex and weights of the babies, the use of assisted reproductive technology, vaginal versus Cesarean delivery, and pregnancy complications. Pregnancy complications included the diagnosis of hypertension, pre-eclampsia, gestational diabetes, kidney infection, need for kidney biopsy, and rejection (for post-transplant pregnancies only). We also asked about the use of medications in pregnancy, focusing on immunosuppression. Responses regarding pregnancy outcomes were validated by manual chart review of a subset of patients who delivered at our institution and therefore had available pregnancy records.

We further inquired whether a woman had a desire for pregnancy in the future, had ever tried to get pregnant after transplant, whether she had been advised not to pursue pregnancy by a health care provider and about the use of contraception.

**Menarche and menopause**

In addition to questions about pregnancy, we asked women about their ages at menarche and whether their periods had stopped before transplant. We also
asked if their periods returned post-transplant, and if so, the timing of return. Finally, we inquired about their current menopausal status, history of oophorectomy and hysterectomy and their ages at last menstrual period.

**Statistical analyses**

Data are presented as percentages for categorical variables and means (standard deviations) or median (interquartile range [IQR]) for continuous variables. We compared pregnancy characteristics and complications post-transplant to pregnancies pretransplant, according to the number of years before transplant (<5 years before transplant, 5–15 years before transplant, and >15 years before transplant). We compared demographic and transplant characteristics of respondents, nonrespondents, and refusals for the survey. We compared categorical variables using either Fisher’s exact test or chi square test, as appropriate, and Student’s t-test for continuous variables. Survey responses are presented as percentages, with the number of missing values noted. To determine clinical features associated with resumption of menses post-transplant, we used logistic regression models. For continuous predictors, we made receiver-operating characteristics curves and identified values with the highest sensitivity and specificity in predicting changes in menstrual cycles. Statistical analyses were conducted using JMP Pro version 14.1.0 (SAS, Cary, NC, USA).

**Results**

There were 818 women ages 18 to 44 at the time of transplant at the three Mayo sites between January 1, 1996 and December 31, 2014. Of the 818 women in the cohort, 91 had died by the time of the mailing, 9 were currently living outside the United States, and 1 woman refused any mailings for research purposes. We were unable to send surveys to women living outside the United States. We mailed a total of 717 surveys and 190 women replied, 93 women refused to take the survey, and 18 more women were found to be deceased. The response rate was 27.2% (excluding women who were found to be deceased from total surveys sent).

Table 1 shows the demographic, transplant, and pregnancy characteristics of women who responded as well as those who did not respond. These data were obtained from chart review (Table 1). Women who responded were more likely to be white, transplanted between the years of 1996 to 2002 at the Rochester, MN site, and to have had a pregnancy after transplant.

### Table 1. Characteristics of Women Who Responded to the Survey, Women Who Refused to Participate, and Women Who Did Not Respond (Including Unclaimed Surveys)

| Characteristic                        | Respondents (n = 190) | Refusals (n = 93) | Nonrespondents (n = 426) | p-Value; Respondents versus refusals | p-Value; Respondents versus nonrespondents |
|---------------------------------------|-----------------------|-------------------|--------------------------|--------------------------------------|-------------------------------------------|
| Age at transplant, mean (SD)          | 34.2 (7.7)            | 36.4 (6.3)        | 33.9 (7.0)               | 0.02a                                | 0.68a                                     |
| Year of transplant, n (%)             | 0.65b                 | 0.007c            |                          |                                      |                                           |
| 1996-2002                             | 45 (23.7)             | 13 (14.0)         | 57 (13.4)                |                                      |                                           |
| 2002-2008                             | 59 (31.1)             | 32 (34.4)         | 156 (36.6)               |                                      |                                           |
| 2008-2014                             | 86 (45.3)             | 48 (51.6)         | 213 (50)                 |                                      |                                           |
| Race, n (%)                           | 0.16c                 | 0.008c            |                          |                                      |                                           |
| White                                 | 148 (77.9)            | 66 (71.0)         | 280 (65.7)               |                                      |                                           |
| African American                      | 12 (6.3)              | 8 (8.6)           | 64 (15.0)                |                                      |                                           |
| Asian or Asian Indian                 | 7 (3.7)               | 3 (3.2)           | 21 (4.9)                 |                                      |                                           |
| American Indian                       | 4 (2.1)               | 2 (2.1)           | 20 (4.7)                 |                                      |                                           |
| Other                                 | 19 (10.0)             | 14 (15.1)         | 41 (9.6)                 |                                      |                                           |
| Site of transplant, n (%)             | 0.06c                 | <0.0001c          |                          |                                      |                                           |
| Rochester, MN                         | 110 (57.9)            | 61 (66.6)         | 165 (38.8)               |                                      |                                           |
| Jacksonville, FL                      | 28 (14.7)             | 18 (19.4)         | 101 (23.7)               |                                      |                                           |
| Scottsdale, AZ                        | 52 (27.4)             | 14 (15.1)         | 160 (37.6)               |                                      |                                           |
| Transplant type, n (%)                | 0.27c                 | 0.42c             |                          |                                      |                                           |
| Living donor                          | 116 (61.1)            | 63 (67.7)         | 244 (57.6)               |                                      |                                           |
| Deceased donor                        | 74 (39.0)             | 30 (32.3)         | 180 (42.4)               |                                      |                                           |
| Preemptive transplant, n (%)          | 25 (13.1)             | 14 (15.0)         | 54 (12.7)                | 0.56b                                | 0.40b                                     |
| BMI at transplant, mean (SD)          | 28.8 (0.6)            | 28.5 (0.9)        | 29.1 (0.5)               | 0.77a                                | 0.77a                                     |
| Ever pregnant before transplant, n (%)| 76 (40)               | 31 (33.3)         | 184 (43.2)               | 0.30c                                | 0.46c                                     |
| Ever pregnant after transplant, n (%) | 19 (10)               | 0 (0)             | 17 (4.0)                 | <0.0001c                             | 0.005c                                     |

*a* Student’s t-test.  
*b* Fisher’s exact test.  
*c* Chi square test.  
BMI, body mass index; SD, standard deviation.
than nonrespondents. Women who refused to complete the survey were older at the time of transplant, and less likely to have had a pregnancy after transplant than women who responded. There were no significant differences in transplant type (living vs. deceased), BMI at the time of transplant, or pregnancy before transplant among the three groups.

There were nine pregnancies with available records to review. We found that self-reported complications, birth weights, and gestational age at delivery were correct with the exception of two errors in the gestational age at delivery—one by 1 week and one by 10 weeks. Both deliveries remained preterm, but one reported a delivery at 20 weeks as opposed to 31 weeks, which could be due to misunderstanding the question or an error in writing 20 rather than 30, as an example.

**Pregnancy history**

Table 2 shows the responses to questions about pregnancy. The majority of women reported being pregnant at some point (59.5%), with a median (range) of 2 (0–10) pregnancies overall. There were 17 women who reported one or more elective abortions before transplant, whereas only 1 woman reported an elective abortion post-transplant. There were 27 women who reported one or more miscarriages before transplant, and 12 women who reported one or more miscarriages after transplant.

There was a total of 204 pretransplant pregnancies, the majority resulting in livebirths (67.1%). There were 141 pregnancies lasting longer than 20 weeks before transplant, with 4 stillbirths and 1 neonatal death. The majority of the women surveyed had pregnancies well before the time of transplant (median [IQR] 14 [8.5–18] years). Table 3 shows the characteristics of pregnancies lasting longer than 20 weeks’ gestation. When looking only at pretransplant pregnancies, there was a trend toward younger maternal age (p<0.0001, trend by analysis of variance [ANOVA]), later gestational age at delivery (p=0.002), and higher birth weight (p<0.001) the further the pregnancy was from the time of transplant.

### Post-transplant pregnancies

A total of 27 women (14.2%) reported having actively tried to become pregnant after transplant, and 11 women (5.8%) reported actively trying to become pregnant at the time of the survey. Forty-two percent of women reported being advised against a pregnancy post-transplant. This recommendation was reported to have come from their nephrologists or kidney transplant providers more than half the time (52.5%). The other half of respondents reported this advice came from obstetricians and gynecologists (16.3%), primary care providers (6.3%), and others (16.3%). Table 4 outlines the reasons respondents reported for being advised against pregnancy. The most common reason given was concern for teratogenicity of immunosuppressant medication or risk of rejection from altering medications (25.9%). There were several women who listed concern for loss of kidney function (17.2%) and concern for exacerbation or complication related to primary kidney disease (14.8%). Eight (9.8%) women reported being given no reason, or the only reason given was that they had a transplant.

There were 52 different pregnancies in 25 unique women at a median (IQR) of 6 (3.75–10.25) years post-transplant. The majority of pregnancies resulted in livebirths (n=30, 57.7%), with the rest being miscarriages (n=22, 42.3%). There were two women whose pregnancies accounted for 9 of the 22 (40.9%) miscarriages.

| Table 2. Responses to Questions About Pregnancy |
|-----------------------------------------------|
| **Pregnancy questions**                       |
| **N= 190**                                     |
| Have you ever been pregnant? n (%)            |
| Yes                                          | 113 (59.4) |
| No                                           | 77 (40.5)  |
| How many of the following have you had before kidney transplant? (median, range) |
| 1 (0–8)                                       |
| No                                            |
| Elective abortions                             |
| 0 (0–3)                                       |
| How many of the following have you had after kidney transplant? (median, range) |
| 0 (0–9)                                       |
| No                                            |
| Elective abortions                             |
| 0 (0–7)                                       |
| Are you planning to become pregnant in the future? n (%) |
| Yes                                          | 11 (5.8)   |
| No                                           | 157 (82.6) |
| Not sure/Had not thought about it              |
| 14 (7.4)                                      |
| Missing                                       |
| 8 (4.2)                                       |
| Since transplant, have you actively tried to become pregnant? n (%) |
| Yes                                          | 27 (14.2)  |
| No                                           | 157 (82.6) |
| Missing                                       |
| 6 (3.2)                                       |
| Have you been advised against pregnancy by a health care provider? n (%) |
| Yes                                          | 80 (42.1)  |
| No                                           | 98 (51.6)  |
| Missing                                       |
| 12 (6.3)                                      |
| If yes, what type of provider recommended against pregnancy? n (%) |
| N= 80                                        |
| Nephrologist or kidney transplant provider    |
| 42 (52.5)                                     |
| Obstetricians–gynecology                      |
| 13 (16.3)                                     |
| Primary care or general internal medicine     |
| 5 (6.3)                                       |
| Other                                         |
| 13 (16.3)                                     |
| Missing                                       |
| 7 (8.8)                                       |
For the 30 pregnancies that lasted longer than 20 weeks, the pregnancy was planned in 86.7% of cases. There were two twin gestations, one of which was conceived with assisted reproductive technology. Only two women reported using assisted reproductive technology. The median (IQR) gestational weeks at delivery was 36 (34.8–37), and 70% of deliveries were preterm. The median (IQR) gestational weight at delivery was 2589 (2098–2863) g. The majority of deliveries were by C-section (63.3%) as opposed to vaginal delivery (36.7%).

The majority of pregnancies were complicated by hypertension in pregnancy (56.7%), although only 50% reported that they were diagnosed with preeclampsia, specifically. One woman reported each of the following complications: gestational diabetes, rejection episode diagnosed by kidney biopsy, and placental abruption. There were four women who reported rising creatinine in pregnancy, only two of which also reported preeclampsia in that pregnancy. In terms of immunosuppression, women took prednisone (76.7%), tacrolimus (90%), and azathioprine (76.7%). Three women reported taking mycophenolate mofetil in pregnancy at some point. Two of these were pregnancies earlier in the cohort period (1998 and 2002). Five women reported being on a beta-blocker for chronic hypertension in pregnancy.

Comparing pre- and post-transplant pregnancies
Table 3 shows the characteristics of pregnancies lasting longer than 20 weeks post-transplant and pretransplant at 3 different time points: 0–5 years before transplant, 5–15 years before transplant, and >15 years before transplant. Pregnancy outcomes were based on patient-reported information via survey responses. In pregnancies post-transplant, recipients were more likely to be older at the time of delivery, with a mean age of 32.7 years. Post-transplant pregnancies were also more likely to be planned (86.7%) relative to pregnancies pretransplant ($p < 0.0001$ for all time points). Deliveries were more likely to be preterm (70%), with an average delivery at 35.7 weeks relative to deliveries post-transplant ($p = 0.001$) and >15 years pretransplant ($p < 0.0001$), but there was no difference in pregnancies 0–5 years pretransplant. Babies born from post-transplant pregnancies were also more likely to be smaller and born via C-section than those born from pregnancies >5 years pretransplant. There was no

### Table 3. Comparison of Post-Transplant Pregnancy Outcomes on Pregnancies Lasting Longer Than 20 Weeks Gestation to Pretransplant Pregnancies at Increasing Intervals from Time of Transplant

| Category                                      | Pretransplant | 0–5 Years prior | 5–15 Years prior | >15 Years prior | General U.S. population rates |
|-----------------------------------------------|---------------|-----------------|------------------|----------------|-------------------------------|
| Age at delivery (years)                       | 32.7 (4.0)    | 28.2 (5.0)      | 37.1 (4.1)       | 35.8 (4.2)     | 36.3 (5.0)                    |
| Planned pregnancy (yes)                       | 26 (86.7%)    | 10 (47.6%)      | 37 (56.1%)       | 38 (33.3%)     | 33 (33.3%)                    |
| Stillbirth                                    | 0 (0%)        | 1 (4.8%)        | 1 (1.5%)         | 2 (3.7%)       | 2 (3.7%)                      |
| Weeks at delivery                            | 35.7 (2.3)    | 35.3 (4.7)      | 37.8 (2.4)       | 38.8 (4.2)     | 39 (4.2)                      |
| Preterm delivery                              | 21 (70%)      | 13 (65%)        | 18 (27.2%)       | 12 (22.2%)     | 18 (22.2%)                    |
| Baby weight (g)                               | 2502 (521)    | 2245 (859)      | 2952 (897)       | 3311 (816)     | 3311 (816)                    |
| Delivery type (% vaginal)                     | 11 (36.7%)    | 10 (47.6%)      | 42 (65.6%)       | 35 (54.8%)     | 35 (54.8%)                    |
| Hypertension                                  | 17 (56.7%)    | 14 (66.7%)      | 28 (42.4%)       | 23 (46.2%)     | 23 (46.2%)                    |
| Preeclampsia                                  | 15 (50%)      | 7 (33.3%)       | 18 (27.3%)       | 12 (22.2%)     | 12 (22.2%)                    |
| Gestational diabetes                          | 1 (3.3%)      | 1 (4.8%)        | 1 (1.5%)         | 4 (7.4%)       | 4 (7.4%)                      |
| Risk of complications or exacerbation of primary disease causing kidney failure | 12 (41.4%)    | 12 (41.4%)      | 23 (35.3%)       | 28 (52.5%)     | 28 (52.5%)                    |
| Risk of loss of kidney function               | 14 (17.2)     | 8 (8.8%)        | 21 (31.9%)       | 23 (43.1%)     | 23 (43.1%)                    |
| Advanced age or postmenopausal                | 5 (6.2)       | 5 (6.2%)        | 10 (15.2%)       | 14 (26.4%)     | 14 (26.4%)                    |
| Personal history of pregnancy related complications | 4 (4.9%)     | 4 (4.9%)        | 7 (10.6%)        | 8 (15.1%)      | 8 (15.1%)                     |
| Uncontrolled or difficult to control hypertension | 2 (2.5)     | 2 (2.5%)        | 4 (6.1%)         | 4 (7.7%)       | 4 (7.7%)                      |
| Too early in post-transplant course            | 2 (2.5)       | 2 (2.5%)        | 3 (4.6%)         | 4 (7.6%)       | 4 (7.6%)                      |
| General concern regarding health of mother and/or fetus | 16 (19.8)    | 16 (19.8%)      | 24 (36.5%)       | 30 (55.5%)     | 30 (55.5%)                    |
| Previous tubal ligation or uterine ablation   | 2 (2.5)       | 2 (2.5%)        | 3 (4.6%)         | 4 (7.7%)       | 4 (7.7%)                      |
| Health concern unrelated to kidney disease or transplant status | 7 (8.6%)     | 7 (8.6%)        | 10 (15.2%)       | 14 (26.4%)     | 14 (26.4%)                    |

All data presented as n (%).  
*Fisher’s exact test for categorical variables and Student’s t-test for continuous variables. All in comparison to post-transplant pregnancies.  
Data from National Vital Statistics Report 2020 on Fetal Death.  
Data from National Vital Statistics Report 2019 on Births.

### Table 4. Reason for Being Advised Against Pregnancy

| Reason for Being Advised Against Pregnancy | N = 81 |
|-------------------------------------------|--------|
| Reasons given for being advised against pregnancy,* n (%) |        |
| No reason offered or only reason having had a transplant | 8 (9.8) |
| Teratogenicity of immunosuppressant medications or concern that adjusting medications would lead to rejection | 21 (25.9) |
| Risk of complications or exacerbation of primary disease causing kidney failure | 12 (14.8) |
| Risk of loss of kidney function | 14 (17.2) |
| Advanced age or postmenopausal | 5 (6.2) |
| Personal history of pregnancy related complications | 4 (4.9) |
| Uncontrolled or difficult to control hypertension | 2 (2.5) |
| Too early in post-transplant course | 2 (2.5) |
| General concern regarding health of mother and/or fetus | 16 (19.8) |
| Previous tubal ligation or uterine ablation | 2 (2.5) |
| Health concern unrelated to kidney disease or transplant status | 7 (8.6) |

*Nos. add up to greater than 81 as women could list more than 1 reason.
difference in rates of hypertension or gestational diabetes between pregnancies pre- and post-transplant. Pregnancies post-transplant were more likely to be complicated by preeclampsia than those pregnancies >5 years pretransplant; however, there was no difference relative to pregnancies 0–5 years pretransplant. Rates of stillbirth were very low in all time periods.

Contraception

Only 95 women (50%) reported having used contraception at any point after transplantation, and 68 women (35.8%) were using contraception at the time of survey response. Contraception was used for a median (range) of 10 (5–16.8) years. Of the 68 women using contraception at the time of survey response, 45% were using permanent sterilization, including bilateral tubal ligation (20.6%) and vasectomy (25%). Long-acting reversible contraceptives were also commonly reported, including an intrauterine device with levonorgestrel in 12 (17.6%) women. Less effective methods, such as condoms/barrier and natural family planning methods, were reported by 14 (20.6%) and 3 (2.9%) women, respectively.

Menopausal characteristics

Details of the responses to questions regarding menopause and menstruation are shown in Table 5. Thirty-seven percent of respondents were premenopausal, 14.2% were perimenopausal, 27.9% were postmenopausal, and 17.4% of respondents were unsure of their menopausal status. In women who were postmenopausal, the average age of their last period was 44.5 years, with an IQR of 36–49 years. Twenty-seven women (14.2%) had a hysterectomy, 14 before transplant and 13 post-transplant. Eleven women (5.8%) reported a previous oophorectomy, with five before transplant and six post-transplant.

Approximately one-third of patients (34.2%) reported that their periods had stopped before transplant. Of these patients, 61.5% had their periods return and 38.5% reported that their periods did not return; however 10 of these patients had a hysterectomy, oophorectomy, or both, and these patients were excluded from the logistic regression models. Age at transplant was a significant predictor of menses returning post-transplant (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.70–0.93 per year), with age of 39 having the highest sensitivity (85%) and specificity (92%). Deceased versus living donor transplant, pregnancy before transplant, and transplant site were not significantly different between women who resumed menses and those who did not. The average time from transplant to resumption of menstrual periods was 3 months (range of 2–6.5 months).

Discussion

In this study, we have analyzed the reproductive histories and experiences of 190 patients with a previous kidney transplant using a patient survey. Previous studies have focused more specifically on pregnancy and kidney function before and after transplant, while not exploring other issues related to reproduction. An understanding of pregnancy outcomes and fertility pre- and post-transplant is important for many women with kidney disease who may wish to pursue pregnancy, and this study offers important insights into some of the challenges faced by women with kidney disease. Outcomes such as preeclampsia and preterm
delivery, in particular, were as common in pregnancies within 5 years pretransplant as they were in pregnancies post-transplant, raising important questions about pregnancy timing. Women post-transplant were more likely to have pregnancies at an older age, which carries increased risk of pregnancy complications. Furthermore, the earlier reported age at menopause suggests that the fertile window post-transplant may be shortened in certain women. We found that the majority of pregnancies post-transplant were planned, but that there is room to improve use of contraception post-transplant. Overall, these findings reflect the complexity involved in counseling women with advanced CKD and kidney transplants on reproductive health.

In our cohort, there were important differences in pregnancy outcomes relative to the proximity to kidney transplant. Post-transplant pregnancies, which typically occurred within 4–10 years post-transplant, did have not significantly different outcomes than pregnancies that occurred 0–5 years pretransplant. The high rate of complications in the more immediate pretransplant period likely reflects the presence of advanced CKD, whereas pregnancies >5 years pretransplant likely occurred in the setting of milder, if any, CKD. A meta-analysis examining pregnancy outcomes in CKD patients, which included 10 studies on preeclampsia risk, showed an OR of 10.36 (95% CI 6.28–17.09) for risk of preeclampsia in patients with CKD relative to patients without CKD. Additionally, patients with CKD have been shown to have increased risk of preterm delivery and lower birth weight babies, as well as increased C-section rates. Interestingly, we did not find a significant difference in outcomes between post-transplant pregnancy and pregnancies <5 years before transplant, presumably when a woman has established CKD. To our knowledge, this is the first study that compares pregnancy outcomes post-transplant relative to pretransplant at multiple time points in a single cohort. However, we do not have data regarding the stage of kidney disease or graft function at the time of pregnancies before and after transplant, which are also important factors.

The rate of preeclampsia reported in post-transplant pregnancies was higher than previously reported in a meta-analysis. However, consistent with previous studies, the rate is well above the average rate in the general nontransplant population in the United States (3.3%). Our study is consistent with previous studies in that risk of preterm delivery, having a small-for-gestational-age baby, and C-section, were all increased post-transplant relative to pregnancies at least 5 years before transplant. Rates of these complications in our study were similar to those described in previous cohort studies. The majority of post-transplant pregnancies reported resulted in live births; however, the miscarriage rate was 42.3%, which is greater than the risk in the general population of 17.1%, although two women accounted for nearly half of these miscarriages. Our results are also likely impacted by nonresponse bias in that we found that women who replied were more likely to have had a post-transplant pregnancy by chart review.

We found that the many patients had been advised against pregnancy by their physicians, most commonly their transplant physicians or nephrologists, although also frequently by obstetricians or primary care providers. Nephrologists frequently report low confidence in providing contraception counseling and report a lack of training in counseling women regarding reproductive health, and thus this raises an important opportunity for multispecialty collaboration. Many of the women reported being advised against pregnancy due to a general concern for their health, while in other cases it was more specifically due to concern for declining kidney function. Pregnancy certainly poses a unique risk to kidney transplant patients. In previous studies, ~25% of patients have experienced a serious complication of pregnancy from a post-transplant pregnancy. However, several patients reported not being provided the reason or not understanding the reason for avoiding pregnancy, suggesting that providers may not be fully counseling women on their reproductive options. Despite the importance of contraceptive counseling in this patient population, only 50% of patients surveyed reported using contraception at any point post-transplant, although highly effective methods, such as sterilization and long-acting reversible contraceptives, were reported with high frequency, and 86.7% of post-transplant pregnancies were planned. This represents an area for clinical improvement, as patients would benefit from multispecialty collaboration and counseling on contraception and reproductive health. Individualized counseling is of utmost importance as different patients may have different perspectives on the risks and benefits of pursuing pregnancy and it can be difficult to quantify different priorities. This study did not address the individual’s relative prioritization of fertility to transplant health and graft function.

Reproductive counseling is also essential due to risk of teratogenicity associated with mycophenolate mofetil. In our study, the majority of women were on
prednisone, azathioprine, and tacrolimus during their post-transplant pregnancies. These are all known to be safe immunosuppressant medications in pregnancy.\textsuperscript{1,21} Three women were on mycophenolate mofetil during their pregnancies at some point, two of them early in the cohort (1998 and 2002). The most common reported reason for being advised against pregnancy was concern regarding teratogenicity of medications or need for medication changes, indicating that patients are being counseled on teratogenicity.

We were able to better understand the rates of return of menstruation after kidney transplant and timing of menopause post-transplant. Notably, our patients reported that their average age of menopause was 45.5 years, which is well below the average age of menopause in U.S. women (51.3 years).\textsuperscript{22} While previous studies have reported earlier menopause in women on dialysis due to disruptions in the hypothalamic–pituitary–gonadal axis, this finding in women who have generally had a restoration in kidney function post-transplant is unexpected.\textsuperscript{8} In women with CKD and end stage kidney disease (ESKD), it is thought that alterations in gonadotropin releasing hormone secretion leads to losses of normal follicle stimulating hormone (FSH) and luteinizing hormone surges, which in turn, cause low estradiol and menstrual irregularities, including amenorrhea. Hyperprolactinemia is also common in ESKD patients and may contribute to abnormal reproductive hormone levels.\textsuperscript{5} In patients with CKD, it remains unclear as to what point kidney function deterioration affects the hypothalamic–pituitary axis. Women with amenorrhea on dialysis have been shown to have lower FSH levels than those consistent with menopausal levels, and thus they are considered to be in a pseudomenopausal state, as often kidney transplant leads to resumption of menstruation.\textsuperscript{5,8,23} We saw this in our survey results, as approximately one-third of surveyed patients reported their periods stopped before transplant, and of those patients, 61.5% had their periods resume post-transplant. Older age at transplant and higher BMI were associated with lower odds of resumption of menstrual cycles after transplant. A better understanding as to why some women do not resume menstrual cycles post-transplant should be a focus of future study.

Our study has several strengths. We were able to include patients from all three Mayo Clinic sites to develop a large and diverse cohort. Using the survey, we were able to review the reproductive history of a large patient population. We were able to assess patient-reported outcomes and gain patient perspectives on reproductive decisions such as contraceptive use and pregnancy counseling. We were able to capture additional pregnancies and pregnancy outcomes using survey methodology that were not available by chart review alone. This is evidenced by the difference in total pregnancies before and after transplant identified in Table 1 by chart review and those in Table 2 by survey responses.

Our main limitation was the response rate of 27%. Additionally, survey data depend on self-reporting, and thus may be subject to recall bias. There were some significant differences between survey respondents and nonrespondents, including age, race, and rates of post-transplant pregnancy. Thus, our results may not fully reflect transplant patients in general. Additionally, we were unable to fully assess the impacts of potential pregnancy without a comprehensive chart review. This was a retrospective study; thus, results should be interpreted with caution. Future work should focus on expanding the patient population to a more diverse cohort and a prospective study. This study offers important insights in the timing of pregnancy and may help clinicians and patients in discussing optimal pregnancy timing.

**Conclusion**

The results of this study show an increased risk of pregnancy-related complications in post-transplant pregnancies relative to pregnancies greater than 5 years before kidney transplant. Outcomes in pregnancies less than 5 years before kidney transplant were similar to those in post-transplant pregnancies. Women in our cohort also reported a younger age of menopause relative to the general population and many women experience amenorrhea related to CKD. These findings offer insights into optimal timing of pregnancy and provide additional information for patients and clinicians.

**Authors’ Contributions**

V.A.D.: Data analysis, drafting of the article, critical revision of the article, and approval of final version. V.D.G. and F.G.C.: conception and design of study, data collection, critical revision of the article, and approval of final version. S.P.: data collection, critical revision of the article, and approval of final version.

A.G.K.: conception and design of study, data collection, data analysis and interpretation, drafting of the article, critical revision of the article, and approval of final version.
Acknowledgments

The authors wish to thank the Mayo Clinic Survey Research Center and the women who responded to the survey for making this study possible.

Data Availability Statement

The data underlying this article are available in the article. The survey is available upon request.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

The study was funded through the Mayo Clinic Transplant Center Scholarly award, Mayo Clinic Division of Nephrology and Hypertension small grants award (Mayo CCaTS grant number UL1TR002377), and the Mayo Clinic Department of Medicine Catalyst Award.

References

1. Webster P, Lightstone L, McKay DB, Josephson MA. Pregnancy in chronic kidney disease and kidney transplantation. Kidney Int 2017;91:1047–1056.
2. Zhang JJ, Ma XX, Hao L, et al. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol 2015;10:1964–1978.
3. Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: A systematic review. Clin J Am Soc Nephrol 2011;6:2587–2598.
4. Hui D, Hladunewich MA. Chronic kidney disease and pregnancy. Obstet Gynecol 2019;133:1182–1194.
5. Ahmed SB, Vitek WS, Holley JL. Fertility, contraception, and novel reproductive technologies in chronic kidney disease. Semin Nephrol 2017;37:327–336.
6. Shah S, Venkatesan RL, Gupta A, et al. Pregnancy outcomes in women with kidney transplant: Metaanalysis and systematic review. BMC Nephrol 2019;20:24.
7. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: Report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant 2005;5:1592–1599.
8. Vellanki K, Hou S. Menopause in CKD. Am J Kidney Dis 2018;71:710–719.
9. Hladunewich MA, Hou S, Oktutayo A, et al. Intensive hemodialysis associates with improved pregnancy outcomes: A Canadian and United States cohort comparison. J Am Soc Nephrol 2014;25:1103–1109.
10. Piccoli GB, Conjin A, Consiglio V, et al. Pregnancy in dialysis patients: Is the evidence strong enough to lead us to change our counseling policy? Clin J Am Soc Nephrol 2010;5:62–71.
11. Levidiotis V, Chang S, McDonald S. Pregnancy and maternal outcomes among kidney transplant recipients. J Am Soc Nephrol 2009;20:2433–2440.
12. Salmela KT, Kyllönen LE, Holmberg C, Gronhagen-Riska C. Impaired renal function after pregnancy in renal transplant recipients. Transplantation 1993;56:1372–1375.
13. Rose C, Gill J, Zalunardo N, Johnston O, Mehrrota A, Gill JS. Timing of pregnancy after kidney transplantation and risk of allograft failure. Am J Transplant 2016;16:2360–2367.
14. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl 2010;7:65–85.
15. Diehl CL, Brost BC, Hogan MC, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: Validation of a preeclampsia questionnaire. Am J Obstet Gynecol 2008;198:e1–13.
16. Kennedy C, Hussein W, Spencer S, et al. Reproductive health in Irish female renal transplant recipients. Ir J Med Sci 2012;181:59–63.
17. Garovic VD, White WM, Vaughan L, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol 2020;75:2323–2334.
18. Bachmann F, Budde K, Gerland M, et al. Pregnancy following kidney transplantation—Impact on mother and graft function and focus on children’s longitudinal development. BMC Pregnancy Childbirth 2019;19:376.
19. Hendren EM, Reynolds ML, Mariani LH, et al. Confidence in women’s health: A Cross border survey of adult nephrologists. J Clin Med 2019;8:176.
20. Coscia LA, Armenti DP, King RW, Sifonits NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 2015;4:42–55.
21. Bramham K. Pregnancy in renal transplant recipients and donors. Semin Nephrol 2017;37:370–377.
22. Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. JAMA 2017;318:2224–2233.
23. Josephson MA, McKay DB. Women and transplantation: Fertility, sexuality, pregnancy, contraception. Adv Chronic Kidney Dis 2013;20:433–440.
24. Hoyert DL, Gregory ECW. Cause of Death Data from Fetal Death File. National Center for Health Statistics. Vital Health Stat 2020:6;4.
25. Martin JA, Hamilton BA, Osterman MJK, Driscoll AK. Births: Final Data for 2019. Vital Health Stat 2021;70:2. 

Abbreviations Used

BMI = body mass index
CI = confidence interval
CKD = chronic kidney disease
ESKD = end stage kidney disease
FSH = follicle stimulating hormone
IQR = interquartile range
OR = odds ratio

Cite this article as: Dines VA, Garovic VD, Parashuram S, Cosio FG, Kattah AG (2021) Pregnancy, contraception, and menopause in advanced chronic kidney disease and kidney transplant, Women’s Health Report 2:1, 488–496, DOI: 10.1089/whr.2021.0053.

Publish in Women’s Health Reports

- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing

liebertpub.com/whr